Antibodies against glutamic acid decarboxylase (GAD), the rate-limiting enzyme in the synthesis of the inhibitory neurotransmitter g-aminobutyric acid (GABA), are associated with various neurological disorders, including stiff-person syndrome, cerebellar ataxia, epilepsy, and limbic encephalitis. This evidence concerns the gene GAD1 and cerebellar ataxia.